CVS Health: The Breakup We Saw Coming Years Ago
CVS Health will split into two public companies by the first half of 2028. Aetna, Caremark, CVS Specialty, Oak Street Health, and Signify Health will stay together under the CVS Health name. The roughly 9,000 drugstores, the mail pharmacy, MinuteClinic, and the Health100 platform leave as CVS Pharmacy.
Wall Street punished the news. Shares fell about 13% in afternoon trading, a loss of nearly $15 billion in market value, even though CVS beat Q3 estimates and raised guidance. The split unwinds the pharmacy half of a 20-year integration strategy. It keeps the insurer-PBM core that regulators target hardest.
The deal at a glance
Announced: November 4, 2026. The Financial Times broke the story the night before.
Structure: Tax-free spin-off. Shareholders will own stock in both companies.
Timing: First half of 2028.
Conditions: Final board approval, an effective Form 10 at the SEC, and tax-free confirmation. CVS warns that it cannot guarantee the terms or timeline.
Leadership: David Joyner stays chairman and CEO of CVS Health. Prem Shah, now group president, becomes CEO of CVS Pharmacy. CVS will name other leaders later.
Capital: CVS expects both companies to carry investment-grade ratings, generate strong free cash flow, and pay dividends. It gave no pro forma financials, debt split, or dividend levels.
Background and history
1963: CVS (Consumer Value Stores) opens in Lowell, Massachusetts. It spun out of its parent, Melville, in 1996.
2006-2007: CVS buys MinuteClinic, then Caremark in a deal Becker's priced at near $21 billion in stock. CVS promised at least $500 million in synergies at the time, per Barclays.
2015: CVS adds Omnicare (about $12.9 billion enterprise value) and Target's pharmacies ($1.9 billion).
2018: CVS closes Aetna, announced at $69 billion and about $78 billion with debt. It stands as the largest healthcare merger in U.S. history.
2023: CVS buys Signify Health ($8 billion) and Oak Street Health ($10.6 billion) to push into value-based care.
2024: Aetna's Medicare Advantage costs spike. Aetna's president exits, CVS launches a $2 billion cost-cut plan with 2,900 layoffs, and shares drop about 24% for the year. Reuters reports a strategic review with bankers. Activist Glenview Capital meets management but denies pushing a breakup. CVS walks away from the idea. Joyner takes over as CEO in October.
2025: CVS books a $5.7 billion goodwill impairment on its healthcare delivery unit in Q3, exits the ACA exchanges for 2026, and absorbs Rite Aid's prescription files. The turnaround runs on eight straight earnings beats.
Background and history
1963: CVS (Consumer Value Stores) opens in Lowell, Massachusetts. It spun out of parent Melville in 1996.
2006-2007: CVS buys MinuteClinic, then Caremark in a deal Becker's prices near $21 billion in stock. CVS promised at least $500 million in synergies at the time, per Barclays.
2015: CVS adds Omnicare (about $12.9 billion enterprise value) and Target's pharmacies ($1.9 billion).
2018: CVS closes Aetna, announced at $69 billion and about $78 billion with debt. It stands as the largest healthcare merger in U.S. history.
2023: CVS buys Signify Health ($8 billion) and Oak Street Health ($10.6 billion) to push into value-based care.
2024: Aetna's Medicare Advantage costs spike. Aetna's president exits, CVS launches a $2 billion cost-cut plan with 2,900 layoffs, and shares drop about 24% for the year. Reuters reports a strategic review with bankers. Activist Glenview Capital meets management but denies pushing a breakup. CVS walks away from the idea. Joyner takes over as CEO in October.
2025: CVS books a $5.7 billion goodwill impairment on its healthcare delivery unit in Q3, exits the ACA exchanges for 2026, and absorbs Rite Aid's prescription files. The turnaround runs on eight straight earnings beats.
The financials
Q3 YoY numbers actually look good on the surface ...
Metric | Q3 2026 | Q3 2025 |
Revenue | $108.4B (+5.4%) | $102.9B |
GAAP diluted EPS | $1.68 | ($3.13) - impairment |
Adjusted EPS | $2.09 (consensus $1.65) | $1.60 |
Net profit | ~ $2.2B | ~ ($4.0B) |
... but the devil is always in the details:
Segments (Q3): Health Care Benefits (Aetna) posted $36.9B revenue, $912M adjusted operating income, a 91.3% medical loss ratio (MLR), and 26.1M medical members. Health Services (Caremark, care delivery) posted $54B and $2.1B, with 481.7M claims. Pharmacy and Consumer Wellness posted $35.5B (down 2%) and $1.6B, with 470M prescriptions.
Guidance: FY2026 adjusted EPS of at least $8.20 (up from $7.90-$8.10), revenue of at least $420B, and operating cash flow of at least $15.5B. Reuters reports 2027 adjusted EPS of at least $8.65 against a $8.53 Street estimate.
Scale: Market value near $117 billion before the drop. About 87 million PBM members, 37 million insurance customers, 1,000+ clinics, and nearly 30,000 pharmacists.
Headwinds: CFO Brian Newman flagged 2027 pressure on the PBM from a government drug discount program (340B in earlier calls), a "less robust selling season," and falling health plan membership.
Caveat: CVS gave no pro forma split. Its reporting segments do not map cleanly onto the two new companies, so any standalone earnings math is an estimate.
The real question is why now?
Many sources - including CVS' leadership - have cited policy and industry forces:
Policy
Federal PBM reform: Congress passed it in the Consolidated Appropriations Act of 2026 (signed Feb. 3). It requires more rebate pass-through, delinking in Part D, and reporting to plan sponsors.
FTC insulin case: Express Scripts settled Feb. 4. Caremark settled July 14. The FTC estimates up to $8.5 billion in consumer savings over 10 years, plus up to $4.5 billion through point-of-sale rebates.
State laws: Arkansas Act 624 bans PBM-owned pharmacies. A federal judge enjoined it in July 2025 after CVS said it would close 23 stores. Tennessee passed a similar law. CVS fights both.
Break Up Big Medicine Act: Sens. Warren and Hawley introduced it in February, with Mark Cuban's backing. It would bar insurers and PBMs from owning providers. Healthcare Uncovered's interpretation implies that simply spinning out drugstores will not comply.
Medicare Advantage: CMS proposed a 0.09% 2027 rate increase in January against Street hopes of 4-6%. CVS shares dropped more than 10% on the news. Joyner still targets MA margin recovery by 2028.
Politics: Healthcare Dive expects more scrutiny of vertical integration in 2027 after the midterms.
Industry
Retail pharmacy is under siege: Mail order, online pharmacies, and big-box stores erode the chains. Walgreens sold Boots and went private under Sycamore Partners.
The conglomerate discount: RBC's Ben Hendrix argues that the low multiple on retail drags down the whole company and hides the earnings of Aetna and Caremark. CVS traded near 11x forward earnings.
The breakup wave: Reuters calls the split part of a string of major corporate separations this decade.
Management's line: Joyner says CVS acts "from a position of strength," not distress, and that regulation did not drive the call. Skeptics disagree. Joyner did concede regulation was one factor, and CVS's investor deck says the split helps both companies adapt to regulatory dynamics.
What the two companies will look like
CVS Health (healthcare solutions company), led by Joyner
Assets: Aetna, Caremark, CVS Specialty, Oak Street Health, Signify Health.
Profile: A UnitedHealth/Optum or Cigna/Evernorth lookalike: insurer, PBM, specialty pharmacy, and care delivery under one roof.
Focus: Aetna's Medicare Advantage margin recovery, the PBM's shift to net-cost pricing, value-based care for seniors, and specialty and GLP-1 volume. Joyner says the structure keeps integration where he sees it paying off: Aetna to Caremark, and Aetna to care delivery.
CVS Pharmacy, led by Shah
Assets: About 9,000 stores, the mail pharmacy, MinuteClinic (including virtual care), and Health100, an AI-native navigation and engagement platform that launched in March.
Focus: Stand-alone retail with the CostVantage reimbursement model. Per Leerink's Michael Cherny, the pharmacy has won share and stabilized gross margins. Shah will pursue broader deals with payers, PBMs, and manufacturers, including CVS's former siblings.
Glue: Joyner told analysts the synergies will survive through commercial agreements, adding "we don't need the integration of an operating structure." Health100 serves as "connective tissue." Cherny notes that preferred-network deals let Caremark keep favoring CVS stores.
First since 2006: CVS returns to a pure-play pharmacy chain for the first time since it bought Caremark.
Who advised
Goldman Sachs & Co.: Lead financial and strategic adviser.
Consello: Financial and strategic adviser.
Wachtell, Lipton, Rosen & Katz: Legal counsel.
The release names no private equity sponsor, consultancy, or additional bank. In 2024, Reuters said CVS worked with unnamed financial advisers. Glenview Capital, a roughly 1% holder, met management that year but denied it pushed for a breakup.
What the experts say
Analysts and investors
UBS, Kevin Caliendo: The market reads the split as a "defensive move against regulation" rather than an offensive one.
Barclays, Andrew Mok: Investors want financial detail. He recalls the $500 million Caremark synergy promise.
J.P. Morgan, Lisa Gill: She sees some logic to the split.
Leerink, Michael Cherny: He called the plan a shock, then called the selloff overblown. He thinks it may ease state legislative pressure.
Morningstar, Julie Utterback: CVS carries the most vertical-integration exposure in the industry, so it moved before a legal or legislative ruling forced its hand.
Bahl & Gaynor, Kevin Gade: He flags an "earnings hiccup" in 2027 against faster-growing rivals.
Consultants and industry voices
Forrester, Arielle Trzcinski: "Now, CVS Health is effectively acknowledging that bigger isn't always better." She also warns that more handoffs and disconnected data will fall on consumers.
Adam Fein (Drug Channels): Calls the split a late admission that Pharmacy-Caremark synergies were "oversold from the start."
Michael Abrams (Numerof & Associates): Asks whether the move pressures UnitedHealth and Cigna. He says time will tell.
Ari Gottlieb (A2 Strategy): Most federal scrutiny targets PBM-insurer ties, and those stay together.
Aabed Meer (Aphias Capital, private equity): Splitting senior care (stays) from walk-in care (leaves) shows CVS still values integrated care delivery.
Samir Batra (Health Innovation Pitch): Declares "Vertical integration is dead," yet notes the insurer-PBM core survived.
Critics and conflict-of-interest voices
Mark Cuban: Called it "brilliant financial engineering" that helps shareholders short-term. He says costs will not change.
AJ Loiacono (Judi Health): CVS still owns a dispensing business, and CVS Specialty stays with the PBM and insurer. He questions independence while both keep the CVS name.
Wendell Potter (Healthcare Uncovered): Predicts history will remember "a corporate reorganization" rather than a breakup.
My read
As Adam Fein pointed out, I believe the pharmacy-Caremark synergy was more hype than a strategic plan. What could have been never became. That being said, I don't believe the two companies will decouple in operations and supply chain simply because they're split up on paper. The jury is still out because there are a few unanswered questions.
CVS peeled off the lowest-margin, lowest-multiple piece and kept the engine regulators fear or, at least, dislike. That helps the pharmacy business get valued on its own and helps Aetna and Caremark shed a conglomerate discount. However, I share Ari Gotlieb's opinion that this does not end the insurer-PBM conflict that federal lawmakers are targeting. The market's 13% drop says investors want proof before they pay for the story. The Form 10 will answer some of the key questions: the commercial agreements, the debt split, and the standalone margins, but divorces don't simply "finalize" once a separation agreement is signed.
As expected, the move has created murmurs around the market about what competitors like UnitedHealth Group and Cigna will do, and my short answer is not much, if anything. CVS's move makes them look more like UHG and Cigna. However, I expect more reorganization across the conglomerates because the policy threats are very real.
What to watch
The Form 10 and the terms of the Caremark-to-CVS Pharmacy commercial agreements.
Whether Break Up Big Medicine moves in a new Congress, and how its text treats CVS Specialty.
Whether UnitedHealth and Cigna face pressure to follow.
The final 2027 Medicare Advantage rate and Caremark's 2027 membership.
Comments